C

Classys Inc
KOSDAQ:214150

Watchlist Manager
Classys Inc
KOSDAQ:214150
Watchlist
Price: 57 700 KRW 0.7% Market Closed
Market Cap: ₩3.8T

P/OCF

21.8
Current
35%
Cheaper
vs 3-y average of 33.5

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
21.8
=
Market Cap
₩3.5T
/
Operating Cash Flow
₩163.9B

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
21.8
=
Market Cap
₩3.5T
/
Operating Cash Flow
₩163.9B

Valuation Scenarios

Classys Inc is trading below its 3-year average

If P/OCF returns to its 3-Year Average (33.5), the stock would be worth ₩88 520.69 (53% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-59%
Maximum Upside
+53%
Average Downside
0%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 21.8 ₩57 700
0%
3-Year Average 33.5 ₩88 520.69
+53%
5-Year Average 30.4 ₩80 325.06
+39%
Industry Average 14 ₩37 167.61
-36%
Country Average 9 ₩23 774.37
-59%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
KR
Classys Inc
KOSDAQ:214150
3.8T KRW 21.8 27.1
US
Intuitive Surgical Inc
NASDAQ:ISRG
170B USD 56.1 59.5
US
Abbott Laboratories
NYSE:ABT
160.6B USD 16.8 25.6
US
Stryker Corp
NYSE:SYK
126.1B USD 25 38.8
IE
Medtronic PLC
NYSE:MDT
107.5B USD 14.8 23.3
US
Boston Scientific Corp
NYSE:BSX
97.4B USD 21.5 33.6
DE
Siemens Healthineers AG
XETRA:SHL
40.6B EUR 13.1 18.8
US
Edwards Lifesciences Corp
NYSE:EW
46.3B USD 29 43.1
US
IDEXX Laboratories Inc
NASDAQ:IDXX
44.7B USD 37.8 42.2
US
Becton Dickinson and Co
NYSE:BDX
44.1B USD 13 25.1
US
Resmed Inc
NYSE:RMD
32B USD 16.7 21.5

Market Distribution

Higher than 76% of companies in Korea
Percentile
76th
Based on 1 012 companies
76th percentile
21.8
Low
0.2 — 4.2
Typical Range
4.2 — 16.6
High
16.6 —
Distribution Statistics
Korea
Min 0.2
30th Percentile 4.2
Median 9
70th Percentile 16.6
Max 2 215 132.4

Classys Inc
Glance View

Market Cap
3.8T KRW
Industry
Health Care

Classys Inc., a South Korean powerhouse in the world of aesthetic medical devices, has carved a niche for itself by capitalizing on the soaring demand for non-invasive beauty treatments. Founded in 2007, the company quickly identified a growing market shift towards minimally invasive procedures, and leveraged its technological prowess to develop cutting-edge solutions. Focusing on continuous innovation, Classys has developed a robust portfolio of high-quality products, including popular devices like Clatuu Alpha for fat reduction and Ultraformer for skin lifting. These devices cater to clinics and professionals seeking reliable, effective solutions for their clients' aesthetic needs. The company strategically invests in research and development to stay ahead in this highly competitive sector, continually upgrading its offerings to suit market trends. Operating in over 60 countries, Classys has effectively harnessed the power of global distribution networks and strategic partnerships to bolster its market presence. The company's business model primarily revolves around direct sales and distribution agreements, generating revenue by selling advanced aesthetic devices to medical professionals, clinics, and distributors worldwide. By providing training and after-sales services, Classys ensures customer satisfaction and fosters long-term relationships, which are crucial for repeat business. Additionally, its strong emphasis on compliance with international safety standards and certifications has bolstered its reputation, enabling the company to expand its footprint in emerging markets. This strategic approach has allowed Classys to maintain steady growth in an industry where technological advancements and consumer preferences are in constant flux.

Intrinsic Value
57 469.23 KRW
Fairly Valued
Intrinsic Value
Price ₩57 700
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett